Published in Lab Business Week, July 3rd, 2005
This is the largest single order for the Therapik(R) product to date. This is a single order, non-exclusive arrangement, for the marketing company to test market Therapik(R) and determine their interest in pursuing an exclusive marketing and sales arrangement for Therapik(R) in the US market. Michael Jenkins, President & CEO of Jenex said "We are optimistic about this test market with Therapik(R) and the licensing potential in the United States that could deliver significant sales and revenue opportunities for Jenex."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.